UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.27-36.e1

2015

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.553-556.e3

2015

Volltextzugriff (PDF)

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Volltextzugriff (PDF)

Research gaps in psoriasis: Opportunities for future studies

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.146-167

2014

Volltextzugriff (PDF)

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Volltextzugriff (PDF)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1029-1072

2019

Volltextzugriff (PDF)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1073-1113

2019

Volltextzugriff (PDF)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1445-1486

2020

Volltextzugriff (PDF)

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Journal of the American Academy of Dermatology, 2019-09, Vol.81 (3), p.775-804

2019

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Volltextzugriff (PDF)

New and emerging therapies in psoriasis

Seminars in cutaneous medicine and surgery, 2014-03, Vol.33 (2 Suppl 2), p.S37-S41

2014

Volltextzugriff (PDF)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Advances in therapy, 2022-05, Vol.39 (5), p.2256-2269

2022

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(85)
magazinearticle
(1)

Sprache

Englisch
(86)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(73)
Life Sciences & Biomedicine
(72)
Dermatology
(62)
Psoriasis - Drug Therapy
(54)
Female
(44)
Male
(44)
Middle Aged
(37)
Biological And Medical Sciences
(36)
Medical Sciences
(36)
Psoriasis
(36)
Adult
(35)
Treatment Outcome
(29)
Severity Of Illness Index
(26)
Antibodies, Monoclonal - Therapeutic Use
(22)
Double-Blind Method
(20)
Psoriasis. Parapsoriasis. Lichen
(20)
Aged
(18)
Antibodies, Monoclonal - Adverse Effects
(18)
Antibodies, Monoclonal - Administration & Dosage
(15)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Research gaps in psoriasis: Opportunities for future studies

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

New and emerging therapies in psoriasis

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Aktive Filter

Suchergebnisse filtern